Zacks Investment Research downgraded DBV Technologies SA – ADR (NASDAQ:DBVT) to Sell in a report released today.
- Updated: September 27, 2016
Yesterday DBV Technologies SA – ADR (NASDAQ:DBVT) traded -0.45% lower at $37.37. The company’s 50-day moving average is $35.17 and its 200-day moving average is $33.27. The last stock close price is up 11.81% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 64,642 shares of the stock were exchanged, down from an average trading volume of 79,969
Zacks Investment Research has downgraded DBV Technologies SA – ADR (NASDAQ:DBVT) to Sell in a report released on 9/27/2016.
See Chart Below
DBV Technologies SA – ADR has a 52 week low of $22.55 and a 52 week high of $39.84 The company’s market cap is currently $0.
In addition to Zacks Investment Research reporting its target price, a total of 7 firms have issued a report on the stock. The consensus target price is $53.50 with 4 firms rating the stock a strong buy, 3 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.
General Information About DBV Technologies SA – ADR (NASDAQ:DBVT)
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.